Astex Pharmaceuticals, a pharmaceutical company dedicated to small molecule therapeutics for oncology and central nervous system diseases, entered into a worldwide research collaboration and license agreement with Merck to identify small molecule candidates with activity towards a tumor suppressor protein for the treatment of cancer. Astex will apply its fragment-based drug discovery platform to develop compounds targeting multiple forms of the p53 tumor suppressor protein and provide Merck w...